Page 381 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 8 of 8 Original Research

Appendix 1

TABLE 1-A1: Comparison of Griffiths mental development scales quotients in
those whose mothers had antiretroviral therapy for prevention of mother-to-child
transmission of HIV or not reported as mean (standard deviation).
Scale Yes PMTCT No PMTCT p
N = 24 N = 4
Locomotor 96.9 (14) 92 (15) 0.51
Personal–social 104.0 (15) 111.8 (6) 0.22
Hearing-and-language 112.1 (12) 118.0 (8) 0.34
Eye–hand coordination 107.5 (16) 101.5 (7) 0.38
Performance (visual–spatial) 101.5 (15) 90 (4.7) 0.06
General Griffiths 104.6 (11) 103.3 (3) 0.84
PMTCT, prevention of mother-to-child transmission.

TABLE 2-A1: Comparison of participant characteristics for those who had
detectable and undetectable viral loads at Griffiths mental development scales
testing reported as mean (standard deviation).
Viral load at testing Detectable Undetectable p
VL n = 9 VL n = 20
Birth weight 2912.2 (576) 3042.5 (475) 0.37
Baseline VL copies 45105 (70493) 16000 (318345) 0.36
(n = 8) (n = 18)
ART start days from birth 9.3 (6.4) 5.8 (3.8) 0.14
CD4 closest to GMDS
Absolute count 2061.2 (1035) 2180.8 (560) 0.25
CD4% 30.8 (2.7) 35.4 (8.1) 0.21
CD8 closest to GMDS
Absolute count 2348.1 (2092) 1723.7 (948) 0.56
CD8% 30.2 (8.7) 26.3 (10.5) 0.26
CD4/CD8 ratio closest to GMDS 1.2 (0.6) 1.6 (0.8) 0.21
CD4%/CD8% ratio closest to 1.15 (0.6) 1.6 (0.9) 0.17
GMDS
CD4 baseline
Absolute count 2040.6 (816) 2099.6 (818) 0.69
CD4% 40.0 (12.4) 47.1 (14.4) 0.26
Growth: WHO z-scores for age
Weight -0.0 (1.1) -0.13 (0.8) 0.87
Head circumference 0.37 (0.8) 0.17 (1.1) 0.52
Length -1.02 (1.1) -1.13 (1.0) 0.71
ART, Antiretroviral therapy; GMDS, Griffiths Mental Development Scale; VL, viral load.
TABLE 3-A1: Summary of scores on the Griffiths mental development scales
locomotor and General Griffiths from controls on South African studies at similar
ages.
Author/study Age Locomotor General
Griffiths
Perez: non-anaemic controls 34 9 months 136 127.0
Davies: non-foetal alcohol syndrome controls 33 7–12 months 100 104.0
Laughton: HIV exposed uninfected controls 10 11 months 102 107.0
Current study 11 months 95.9 103.6
Amod: South African sample 29 13–16 months 98 102.0
Springer: HIV exposed uninfected controls 32 17–19 months 87 87.0

http://www.sajhivmed.org.za 374 Open Access